Skip to main content
Top
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Protein expression mapping of normal human breast epithelium

Author: Rob Clarke

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Breast cancer prognosis and treatment could theoretically be improved by definition of the tumour-specific changes that take place in both gene expression and, by inference, in the protein expression profile, herein termed the proteome. Proteomics describes the unique protein expression profile of a sample by using refined two-dimensional gel analysis to produce a protein expression map (PEM) that can include information on post-translational modification and subcellular localisation. Use of normal breast epithelial cells as a baseline for these studies may be hindered by use of established cell lines that may be unrepresentative of normal breast epithelium, or conversely, by the heterogeneity of cell phenotypes contained in normal breast tissue. …
Literature
1.
go back to reference Page MJ, Amess B, Reid Townsend R, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O'Hare MJ: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA. 1999, 96: 12589-12594.CrossRefPubMedPubMedCentral Page MJ, Amess B, Reid Townsend R, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O'Hare MJ: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA. 1999, 96: 12589-12594.CrossRefPubMedPubMedCentral
Metadata
Title
Protein expression mapping of normal human breast epithelium
Author
Rob Clarke
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66621

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine